Client situation: A company developing gene therapies for blood disorders needed confidence in their cell and gene therapy operating model build-out assumptions before committing to headcount and resourcing decisions.

Eradigm’s approach:

• Defined assumptions and decision thresholds upfront with the client team
• Benchmarked peer CGT operating models across development phases
• Tested assumptions through targeted expert interviews with commercial, medical, and operations stakeholders
• Translated findings into mapped cross-functional roles, headcount guidance, and responsibilities across the launch lifecycle

What the client achieved:

• Hypothesis-led primary: beliefs tested, not anecdotes collected
• Cross-functional sourcing: commercial, medical, and operations perspectives all included
• Practical outputs: clear roles and interfaces the team could adopt, designed to be presented to a C-suite audience

Client voice: “The interviews surfaced a few blind spots for us. It made our assumptions tangible and we left with a clearer view of what needs to be true, and what we should adjust.” — VP Portfolio Strategy, cell and gene therapy company